首页 > 最新文献

Human Antibodies最新文献

英文 中文
Assessment of CD40L and TSAB serum level in Graves disease patients. 评估巴塞杜氏病患者血清中的 CD40L 和 TSAB 水平。
Q3 Medicine Pub Date : 2024-09-23 DOI: 10.3233/HAB-240036
Alkhansaa Tariq Jawad, Hayfaa Mahmood Fahad, Ayat Ali Salih

Background: The autoimmune disorder known as Graves' disease. The condition is due to the binding of thyroid-stimulating immunoglobulins to the thyrotropin receptor located on the thyroid gland. The result is an excess of thyroidal hormones. symptoms of hyperthyroidism, and the formation of diffuse goiter.

Objectives: This research intends to quantify the levels of CD40L, TSAB in people who suffer from Graves' disease. It also aims to determine the relationship between TSAB and the duration of the disease, as well as analyze the role of CD40L as a predictive marker for Graves' disease using medcalc Statistical Software version 16.4.3 and SAS (2018).

Methods: In a case-control study, randomly selected 90 graves disease patients were included, the randomly selected patients were divided equally and matched into a case group who have graves disease and graves disease-free patients as a control group. For both groups whole blood sample was examined to compare for (TSAB), and (CD40L) levels determination by ELISA technique.

Results: The average serum levels of CD40L showed a highly significant correlation (P value < 0.01) among the groups examined for Graves' disease. The patient group consisted of 13 males (28.89%) and 32 females (71.11%). No significant correlation was identified between TSAB and the duration of the condition.

Conclusion: Thyroid stimulating antibody (TSAb) test and ultrasonography of the thyroid gland are valuable diagnostic techniques for autoimmune Graves' disease (GD). CD40L could potentially serve as a predictive diagnostic marker for Graves' disease. However, there is no observed link between the duration of the disease and the concentration of TSAB.

背景:巴塞杜氏病是一种自身免疫性疾病:巴塞杜氏病是一种自身免疫性疾病。这种疾病是由于刺激甲状腺的免疫球蛋白与位于甲状腺上的促甲状腺激素受体结合所致。其结果是甲状腺激素过多,出现甲状腺功能亢进症状,并形成弥漫性甲状腺肿:本研究旨在量化巴塞杜氏病患者体内的 CD40L 和 TSAB 水平。研究还旨在确定TSAB与病程之间的关系,并使用medcalc统计软件16.4.3版和SAS(2018)分析CD40L作为巴塞杜氏病预测标志物的作用:在病例对照研究中,随机选取90例巴塞杜氏病患者作为研究对象,将随机选取的患者平均分为病例组(患有巴塞杜氏病)和对照组(无巴塞杜氏病)。对两组患者的全血样本进行检测,通过酶联免疫吸附法测定(TSAB)和(CD40L)水平:结果:在接受检查的巴塞杜氏病患者组中,CD40L的平均血清水平显示出极显著的相关性(P值<0.01)。患者组中有 13 名男性(28.89%)和 32 名女性(71.11%)。TSAB与病程无明显相关性:结论:促甲状腺抗体(TSAb)检测和甲状腺超声波检查是自身免疫性巴塞杜氏病(GD)的重要诊断技术。CD40L有可能成为巴塞杜氏病的预测性诊断标志物。然而,在疾病的持续时间和TSAB的浓度之间并没有观察到任何联系。
{"title":"Assessment of CD40L and TSAB serum level in Graves disease patients.","authors":"Alkhansaa Tariq Jawad, Hayfaa Mahmood Fahad, Ayat Ali Salih","doi":"10.3233/HAB-240036","DOIUrl":"https://doi.org/10.3233/HAB-240036","url":null,"abstract":"<p><strong>Background: </strong>The autoimmune disorder known as Graves' disease. The condition is due to the binding of thyroid-stimulating immunoglobulins to the thyrotropin receptor located on the thyroid gland. The result is an excess of thyroidal hormones. symptoms of hyperthyroidism, and the formation of diffuse goiter.</p><p><strong>Objectives: </strong>This research intends to quantify the levels of CD40L, TSAB in people who suffer from Graves' disease. It also aims to determine the relationship between TSAB and the duration of the disease, as well as analyze the role of CD40L as a predictive marker for Graves' disease using medcalc Statistical Software version 16.4.3 and SAS (2018).</p><p><strong>Methods: </strong>In a case-control study, randomly selected 90 graves disease patients were included, the randomly selected patients were divided equally and matched into a case group who have graves disease and graves disease-free patients as a control group. For both groups whole blood sample was examined to compare for (TSAB), and (CD40L) levels determination by ELISA technique.</p><p><strong>Results: </strong>The average serum levels of CD40L showed a highly significant correlation (P value < 0.01) among the groups examined for Graves' disease. The patient group consisted of 13 males (28.89%) and 32 females (71.11%). No significant correlation was identified between TSAB and the duration of the condition.</p><p><strong>Conclusion: </strong>Thyroid stimulating antibody (TSAb) test and ultrasonography of the thyroid gland are valuable diagnostic techniques for autoimmune Graves' disease (GD). CD40L could potentially serve as a predictive diagnostic marker for Graves' disease. However, there is no observed link between the duration of the disease and the concentration of TSAB.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and characterization of three novel mouse monoclonal antibodies targeting spike protein S1 subunit of Middle East Respiratory Syndrome Corona Virus. 针对中东呼吸综合征冠状病毒尖峰蛋白 S1 亚基的三种新型小鼠单克隆抗体的开发和特征描述。
Q3 Medicine Pub Date : 2024-05-02 DOI: 10.3233/HAB-240016
A. Abbas, S. El-Kafrawy, Ashraf A Tabll, A. Hashem, Tagreed L Al Subhi, M. Alsaadi, E. Azhar
BACKGROUNDMiddle East Respiratory Syndrome Coronavirus is a highly pathogenic virus that poses a significant threat to public health.OBJECTIVEThe purpose of this study is to develop and characterize novel mouse monoclonal antibodies targeting the spike protein S1 subunit of the Middle East Respiratory Syndrome Corona Virus (MERS-CoV).METHODSIn this study, three mouse monoclonal antibodies (mAbs) against MERS-CoV were generated and characterized using hybridoma technology. The mAbs were evaluated for their reactivity and neutralization activity. The mAbs were generated through hybridoma technology by the fusion of myeloma cells and spleen cells from MERS-CoV-S1 immunized mice. The resulting hybridomas were screened for antibody production using enzyme-linked immunosorbent assays (ELISA).RESULTSELISA results demonstrated that all three mAbs exhibited strong reactivity against the MERS-CoV S1-antigen. Similarly, dot-ELISA revealed their ability to specifically recognize viral components, indicating their potential for diagnostic applications. Under non-denaturing conditions, Western blot showed the mAbs to have robust reactivity against a specific band at 116 KDa, corresponding to a putative MERS-CoV S1-antigen. However, no reactive bands were observed under denaturing conditions, suggesting that the antibodies recognize conformational epitopes. The neutralization assay showed no in vitro reactivity against MERS-CoV.CONCLUSIONThis study successfully generated three mouse monoclonal antibodies against MERS-CoV using hybridoma technology. The antibodies exhibited strong reactivity against MERS-CoV antigens using ELISA and dot ELISA assays. Taken together, these findings highlight the significance of these mAbs for potential use as valuable tools for MERS-CoV research and diagnosis (community and field-based surveillance and viral antigen detection).
背景中东呼吸综合征冠状病毒是一种高致病性病毒,对公共卫生构成重大威胁。目的本研究的目的是开发和鉴定针对中东呼吸综合征冠状病毒(MERS-CoV)尖峰蛋白 S1 亚基的新型小鼠单克隆抗体。对这些 mAbs 的反应性和中和活性进行了评估。这些 mAbs 是通过杂交瘤技术将骨髓瘤细胞和 MERS-CoV-S1 免疫小鼠的脾脏细胞融合产生的。结果表明,这三种 mAbs 对 MERS-CoV S1 抗原都有很强的反应性。同样,点式酶联免疫吸附试验(dot-ELISA)也显示了它们特异性识别病毒成分的能力,表明它们具有诊断应用的潜力。在非变性条件下,Western 印迹显示 mAbs 对 116 KDa 的特异性条带有很强的反应性,该条带与推测的 MERS-CoV S1 抗原相对应。然而,在变性条件下没有观察到反应带,这表明抗体能识别构象表位。结论 本研究利用杂交瘤技术成功制备了三种针对 MERS-CoV 的小鼠单克隆抗体。通过酶联免疫吸附和点酶联免疫吸附试验,这些抗体对 MERS-CoV 抗原有很强的反应性。综上所述,这些研究结果凸显了这些 mAbs 作为 MERS-CoV 研究和诊断(社区和现场监测以及病毒抗原检测)的重要潜在用途。
{"title":"Development and characterization of three novel mouse monoclonal antibodies targeting spike protein S1 subunit of Middle East Respiratory Syndrome Corona Virus.","authors":"A. Abbas, S. El-Kafrawy, Ashraf A Tabll, A. Hashem, Tagreed L Al Subhi, M. Alsaadi, E. Azhar","doi":"10.3233/HAB-240016","DOIUrl":"https://doi.org/10.3233/HAB-240016","url":null,"abstract":"BACKGROUND\u0000Middle East Respiratory Syndrome Coronavirus is a highly pathogenic virus that poses a significant threat to public health.\u0000\u0000\u0000OBJECTIVE\u0000The purpose of this study is to develop and characterize novel mouse monoclonal antibodies targeting the spike protein S1 subunit of the Middle East Respiratory Syndrome Corona Virus (MERS-CoV).\u0000\u0000\u0000METHODS\u0000In this study, three mouse monoclonal antibodies (mAbs) against MERS-CoV were generated and characterized using hybridoma technology. The mAbs were evaluated for their reactivity and neutralization activity. The mAbs were generated through hybridoma technology by the fusion of myeloma cells and spleen cells from MERS-CoV-S1 immunized mice. The resulting hybridomas were screened for antibody production using enzyme-linked immunosorbent assays (ELISA).\u0000\u0000\u0000RESULTS\u0000ELISA results demonstrated that all three mAbs exhibited strong reactivity against the MERS-CoV S1-antigen. Similarly, dot-ELISA revealed their ability to specifically recognize viral components, indicating their potential for diagnostic applications. Under non-denaturing conditions, Western blot showed the mAbs to have robust reactivity against a specific band at 116 KDa, corresponding to a putative MERS-CoV S1-antigen. However, no reactive bands were observed under denaturing conditions, suggesting that the antibodies recognize conformational epitopes. The neutralization assay showed no in vitro reactivity against MERS-CoV.\u0000\u0000\u0000CONCLUSION\u0000This study successfully generated three mouse monoclonal antibodies against MERS-CoV using hybridoma technology. The antibodies exhibited strong reactivity against MERS-CoV antigens using ELISA and dot ELISA assays. Taken together, these findings highlight the significance of these mAbs for potential use as valuable tools for MERS-CoV research and diagnosis (community and field-based surveillance and viral antigen detection).","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"26 47","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141019899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of vitamin D against COVID-19 infection, progression and severity. 维生素 D 对 COVID-19 感染、进展和严重程度的作用。
Q3 Medicine Pub Date : 2024-04-10 DOI: 10.3233/HAB-240009
H. S. Ahmed, Hind Sh Ahmed, Haylim N. Abud
BACKGROUNDThe number of coronavirus disease-19 (COVID-19) positive patients and fatalities keeps rising. It is important to recognize risk factors for severe outcomes. Evidence linking vitamin D deficiency and the severity of COVID-19 is tangential but substantial - relating to race, obesity, and institutionalization.OBJECTIVEThis study aims to examine the function of vitamin D and nutritional defense against infections such as COVID-19, which is the goal of this research.METHODSThis study includes observational cohort, cross-sectional, and case-control studies that estimated variances in serum levels of vitamin D among patients with mild or severe forms of COVID-19, and in patients who died or were discharged from hospitals. Studies that assessed the risk of developing severe disorder or death in patients with vitamin D deficiency, defined as levels of vitamin D< 20 ng/mL, were also encompassed.RESULTSIn a retrospective study on 464,383 individuals, results showed that individuals who had the highest risks for severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection, and for COVID-19 severity when infected, had vitamin D levels < 30 nmol/L; Odds Ratio (OR) were 1.246 [95% Confidence Interval (CI): 1.210-1.304] and 1.513 [95%CI: 1.230-1.861], respectively. Additionally, in a retrospective observational study of 191,779 individuals in the USA. The SARS-CoV-2 positivity rate was greater in the 39,190 subjects with vitamin D < 20 ng/mL [12.5%, 95% C.I. 12.2-12.8%] than in the 27,870 subjects with sufficient serum vitamin D levels [8.1%, 95% C.I. 7.8-8.4%] and in the 12,321 subjects with serum vitamin D ⩾ 55 ng/mL [5.9%, 95% C.I. 5.5-6.4%].CONCLUSIONPeople hospitalized for COVID-19 should be checked for vitamin D status and supplemented, and high-dose-in testing should be considered in the recovery trial. More importantly, screening for malnutrition and the administration of the best nutritional supplements are essential for the immune system of the human body to function as it should be. Thus, nutritional supplementation is crucial for people with risk factors as well as older adults with compromised immune systems.
背景冠状病毒病-19(COVID-19)阳性患者和死亡人数不断上升。认识导致严重后果的风险因素非常重要。本研究旨在探讨维生素 D 的功能和对 COVID-19 等感染的营养防御,这也是本研究的目标。方法本研究包括观察性队列研究、横断面研究和病例对照研究,这些研究估计了轻度或重度 COVID-19 患者以及死亡或出院患者血清中维生素 D 水平的差异。此外,还包括评估维生素 D 缺乏症(维生素 D 水平< 20 ng/mL)患者罹患严重疾病或死亡风险的研究。结果在一项对 464,383 人进行的回顾性研究中,结果显示感染严重急性呼吸系统综合征冠状病毒(SARS-CoV-2)和感染 COVID-19 严重程度风险最高的人的维生素 D 水平< 30 nmol/L;Odds Ratio (OR) 分别为 1.246 [95% Confidence Interval (CI):1.210-1.304] 和 1.513 [95%CI: 1.230-1.861]。此外,在一项针对美国 191 779 人的回顾性观察研究中。维生素 D < 20 ng/mL 的 39 190 名受试者的 SARS-CoV-2 阳性率[12.5%,95%C.I. 12.2-12.8%]高于血清维生素 D 水平充足的 27 870 名受试者[8.1%,95%C.I. 7.8-8.4%],也高于血清维生素 D 含量不足的 12 370 名受试者[8.1%,95%C.I. 7.8-8.4%]。结论COVID-19住院患者应检查维生素D状态并补充维生素D,在康复试验中应考虑高剂量检测。更重要的是,营养不良筛查和最佳营养补充剂的使用对于人体免疫系统发挥其应有功能至关重要。因此,对于有风险因素的人以及免疫系统受损的老年人来说,营养补充至关重要。
{"title":"The role of vitamin D against COVID-19 infection, progression and severity.","authors":"H. S. Ahmed, Hind Sh Ahmed, Haylim N. Abud","doi":"10.3233/HAB-240009","DOIUrl":"https://doi.org/10.3233/HAB-240009","url":null,"abstract":"BACKGROUND\u0000The number of coronavirus disease-19 (COVID-19) positive patients and fatalities keeps rising. It is important to recognize risk factors for severe outcomes. Evidence linking vitamin D deficiency and the severity of COVID-19 is tangential but substantial - relating to race, obesity, and institutionalization.\u0000\u0000\u0000OBJECTIVE\u0000This study aims to examine the function of vitamin D and nutritional defense against infections such as COVID-19, which is the goal of this research.\u0000\u0000\u0000METHODS\u0000This study includes observational cohort, cross-sectional, and case-control studies that estimated variances in serum levels of vitamin D among patients with mild or severe forms of COVID-19, and in patients who died or were discharged from hospitals. Studies that assessed the risk of developing severe disorder or death in patients with vitamin D deficiency, defined as levels of vitamin D< 20 ng/mL, were also encompassed.\u0000\u0000\u0000RESULTS\u0000In a retrospective study on 464,383 individuals, results showed that individuals who had the highest risks for severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection, and for COVID-19 severity when infected, had vitamin D levels < 30 nmol/L; Odds Ratio (OR) were 1.246 [95% Confidence Interval (CI): 1.210-1.304] and 1.513 [95%CI: 1.230-1.861], respectively. Additionally, in a retrospective observational study of 191,779 individuals in the USA. The SARS-CoV-2 positivity rate was greater in the 39,190 subjects with vitamin D < 20 ng/mL [12.5%, 95% C.I. 12.2-12.8%] than in the 27,870 subjects with sufficient serum vitamin D levels [8.1%, 95% C.I. 7.8-8.4%] and in the 12,321 subjects with serum vitamin D ⩾ 55 ng/mL [5.9%, 95% C.I. 5.5-6.4%].\u0000\u0000\u0000CONCLUSION\u0000People hospitalized for COVID-19 should be checked for vitamin D status and supplemented, and high-dose-in testing should be considered in the recovery trial. More importantly, screening for malnutrition and the administration of the best nutritional supplements are essential for the immune system of the human body to function as it should be. Thus, nutritional supplementation is crucial for people with risk factors as well as older adults with compromised immune systems.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"2005 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140718594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The rebirth of epitope-based patent claims. 基于表位的专利申请的重生。
Q3 Medicine Pub Date : 2024-04-01 DOI: 10.3233/HAB-240006
Ulrich Storz
BACKGROUNDPatent protection of therapeutic antibodies and T cell receptors is an important tool to enable the path to the market. In view of the substantial spendings for R&D and regulatory approval, sponsors expect exclusivity for their drug for a given period of time. Different categories exist to protect therapeutic antibodies and T cell receptors. One of these categories are epitope-based patent claims, with regard to which in the different jurisdictions, different patentability standards exist, which, furthermore, are constantly changed by courts and lawmakers.OBJECTIVEThis article tries to explain the patentability issues related to epitope-based patent claims.METHODSFor this purpose, an overview is given on the respective legal provisions and court decisions.RESULTSThe study reveals that the respective patentability standards are constantly changed by courts and lawmakers.CONCLUSIONSCompanies developing therapeutic antibodies or T cell receptors need to consider these developments in their strategic planning.
背景治疗性抗体和 T 细胞受体的专利保护是帮助药物进入市场的重要工具。鉴于研发和监管审批花费巨大,申办者希望其药物在一定时期内享有独占权。治疗性抗体和 T 细胞受体有不同的保护类别。其中一类是基于表位的专利要求,不同的司法管辖区有不同的可专利性标准,而且法院和立法者也在不断修改这些标准。结论开发治疗性抗体或 T 细胞受体的公司需要在战略规划中考虑这些发展。
{"title":"The rebirth of epitope-based patent claims.","authors":"Ulrich Storz","doi":"10.3233/HAB-240006","DOIUrl":"https://doi.org/10.3233/HAB-240006","url":null,"abstract":"BACKGROUND\u0000Patent protection of therapeutic antibodies and T cell receptors is an important tool to enable the path to the market. In view of the substantial spendings for R&D and regulatory approval, sponsors expect exclusivity for their drug for a given period of time. Different categories exist to protect therapeutic antibodies and T cell receptors. One of these categories are epitope-based patent claims, with regard to which in the different jurisdictions, different patentability standards exist, which, furthermore, are constantly changed by courts and lawmakers.\u0000\u0000\u0000OBJECTIVE\u0000This article tries to explain the patentability issues related to epitope-based patent claims.\u0000\u0000\u0000METHODS\u0000For this purpose, an overview is given on the respective legal provisions and court decisions.\u0000\u0000\u0000RESULTS\u0000The study reveals that the respective patentability standards are constantly changed by courts and lawmakers.\u0000\u0000\u0000CONCLUSIONS\u0000Companies developing therapeutic antibodies or T cell receptors need to consider these developments in their strategic planning.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"40 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140783676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and characterization of three novel mouse monoclonal antibodies targeting spike protein S1 subunit of Middle East respiratory syndrome corona virus. 针对中东呼吸综合征冠状病毒尖峰蛋白 S1 亚基的三种新型小鼠单克隆抗体的开发和特征描述。
Q3 Medicine Pub Date : 2024-01-01 DOI: 10.3233/HAB-240016
Aymn T Abbas, Sherif A El-Kafrawy, Ashraf A Tabll, Anwar M Hashem, Tagreed L Al Subhi, Mohammed Alsaadi, Esam I Azhar

Background: Middle East Respiratory Syndrome Coronavirus is a highly pathogenic virus that poses a significant threat to public health.

Objective: The purpose of this study is to develop and characterize novel mouse monoclonal antibodies targeting the spike protein S1 subunit of the Middle East Respiratory Syndrome Corona Virus (MERS-CoV).

Methods: In this study, three mouse monoclonal antibodies (mAbs) against MERS-CoV were generated and characterized using hybridoma technology. The mAbs were evaluated for their reactivity and neutralization activity. The mAbs were generated through hybridoma technology by the fusion of myeloma cells and spleen cells from MERS-CoV-S1 immunized mice. The resulting hybridomas were screened for antibody production using enzyme-linked immunosorbent assays (ELISA).

Results: ELISA results demonstrated that all three mAbs exhibited strong reactivity against the MERS-CoV S1-antigen. Similarly, dot-ELISA revealed their ability to specifically recognize viral components, indicating their potential for diagnostic applications. Under non-denaturing conditions, Western blot showed the mAbs to have robust reactivity against a specific band at 116 KDa, corresponding to a putative MERS-CoV S1-antigen. However, no reactive bands were observed under denaturing conditions, suggesting that the antibodies recognize conformational epitopes. The neutralization assay showed no in vitro reactivity against MERS-CoV.

Conclusion: This study successfully generated three mouse monoclonal antibodies against MERS-CoV using hybridoma technology. The antibodies exhibited strong reactivity against MERS-CoV antigens using ELISA and dot ELISA assays. Taken together, these findings highlight the significance of these mAbs for potential use as valuable tools for MERS-CoV research and diagnosis (community and field-based surveillance and viral antigen detection).

背景:中东呼吸综合征冠状病毒是一种高致病性病毒,对公共卫生构成严重威胁:中东呼吸综合征冠状病毒是一种高致病性病毒,对公共卫生构成重大威胁:本研究的目的是开发和鉴定针对中东呼吸综合征冠状病毒(MERS-CoV)尖峰蛋白S1亚基的新型小鼠单克隆抗体:在这项研究中,利用杂交瘤技术生成了三种针对 MERS-CoV 的小鼠单克隆抗体(mAbs),并对其进行了鉴定。对这些 mAbs 的反应性和中和活性进行了评估。这些 mAbs 是通过杂交瘤技术将骨髓瘤细胞和 MERS-CoV-S1 免疫小鼠的脾脏细胞融合产生的。利用酶联免疫吸附试验(ELISA)对杂交瘤产生的抗体进行筛选:结果:酶联免疫吸附试验结果表明,所有三种 mAbs 对 MERS-CoV S1 抗原都有很强的反应性。同样,点式酶联免疫吸附试验(dot-ELISA)也显示了它们特异性识别病毒成分的能力,表明它们具有诊断应用的潜力。在非变性条件下,Western 印迹显示 mAbs 对 116 KDa 的特异性条带有很强的反应性,该条带与推测的 MERS-CoV S1 抗原相对应。然而,在变性条件下没有观察到反应带,这表明抗体能识别构象表位。中和试验显示,抗体在体外对 MERS-CoV 没有反应:结论:本研究利用杂交瘤技术成功产生了三种抗 MERS-CoV 的小鼠单克隆抗体。结论:这项研究利用杂交瘤技术成功地产生了三种抗 MERS-CoV 的小鼠单克隆抗体,这些抗体在 ELISA 和点式 ELISA 检测中对 MERS-CoV 抗原有很强的反应性。综上所述,这些研究结果凸显了这些 mAbs 作为 MERS-CoV 研究和诊断(社区和现场监测以及病毒抗原检测)的重要潜在用途。
{"title":"Development and characterization of three novel mouse monoclonal antibodies targeting spike protein S1 subunit of Middle East respiratory syndrome corona virus.","authors":"Aymn T Abbas, Sherif A El-Kafrawy, Ashraf A Tabll, Anwar M Hashem, Tagreed L Al Subhi, Mohammed Alsaadi, Esam I Azhar","doi":"10.3233/HAB-240016","DOIUrl":"10.3233/HAB-240016","url":null,"abstract":"<p><strong>Background: </strong>Middle East Respiratory Syndrome Coronavirus is a highly pathogenic virus that poses a significant threat to public health.</p><p><strong>Objective: </strong>The purpose of this study is to develop and characterize novel mouse monoclonal antibodies targeting the spike protein S1 subunit of the Middle East Respiratory Syndrome Corona Virus (MERS-CoV).</p><p><strong>Methods: </strong>In this study, three mouse monoclonal antibodies (mAbs) against MERS-CoV were generated and characterized using hybridoma technology. The mAbs were evaluated for their reactivity and neutralization activity. The mAbs were generated through hybridoma technology by the fusion of myeloma cells and spleen cells from MERS-CoV-S1 immunized mice. The resulting hybridomas were screened for antibody production using enzyme-linked immunosorbent assays (ELISA).</p><p><strong>Results: </strong>ELISA results demonstrated that all three mAbs exhibited strong reactivity against the MERS-CoV S1-antigen. Similarly, dot-ELISA revealed their ability to specifically recognize viral components, indicating their potential for diagnostic applications. Under non-denaturing conditions, Western blot showed the mAbs to have robust reactivity against a specific band at 116 KDa, corresponding to a putative MERS-CoV S1-antigen. However, no reactive bands were observed under denaturing conditions, suggesting that the antibodies recognize conformational epitopes. The neutralization assay showed no in vitro reactivity against MERS-CoV.</p><p><strong>Conclusion: </strong>This study successfully generated three mouse monoclonal antibodies against MERS-CoV using hybridoma technology. The antibodies exhibited strong reactivity against MERS-CoV antigens using ELISA and dot ELISA assays. Taken together, these findings highlight the significance of these mAbs for potential use as valuable tools for MERS-CoV research and diagnosis (community and field-based surveillance and viral antigen detection).</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunogenicity of biologics used in the treatment of asthma. 用于治疗哮喘的生物制剂的免疫原性。
Q3 Medicine Pub Date : 2024-01-01 DOI: 10.3233/HAB-240002
Omario A M Neunie, Wardah Rabbani, David Baker, Emma S Chambers, Paul E Pfeffer, Angray S Kang

Objective: Asthma is a major global disease affecting adults and children, which can lead to hospitalization and death due to breathing difficulties. Although targeted monoclonal antibody therapies have revolutionized treatment of severe asthma, some patients still fail to respond. Here we critically evaluate the literature on biologic therapy failure in asthma patients with particular reference to anti-drug antibody production, and subsequent loss of response, as the potential primary cause of drug failure in asthma patients.

Recent findings: Encouragingly, asthma in most cases responds to treatment, including the use of an increasing number of biologic drugs in moderate to severe disease. This includes monoclonal antibody inhibitors of immunoglobulin E and cytokines, including interleukin 4, 5, or 13 and thymic stromal lymphopoietin. These limit mast cell and eosinophil activity that cause the symptomatic small airways obstruction and exacerbations.

Summary: Despite humanization of the antibodies, it is evident that benralizumab; dupilumab; mepolizumab; omalizumab; reslizumab and tezepelumab all induce anti-drug antibodies to some extent. These can contribute to adverse events including infusion reactions, serum sickness, anaphylaxis and potentially disease activity due to loss of therapeutic function. Monitoring anti-drug antibodies (ADA) may allow prediction of future treatment-failure in some individuals allowing treatment cessation and switching therefore potentially limiting disease breakthrough.

综述的目的:哮喘是一种影响成人和儿童的全球性重大疾病,可因呼吸困难导致住院和死亡。尽管靶向单克隆抗体疗法已彻底改变了重症哮喘的治疗,但仍有一些患者无法对其产生反应。在此,我们对有关哮喘患者生物治疗失败的文献进行了批判性评估,特别提到了抗药物抗体的产生和随后的反应消失,这是导致哮喘患者药物治疗失败的潜在主要原因:令人鼓舞的是,哮喘在大多数情况下都能对治疗做出反应,包括在中重度疾病中使用越来越多的生物制剂药物。这包括免疫球蛋白 E 的单克隆抗体抑制剂和细胞因子,包括白细胞介素 4、5 或 13 和胸腺基质淋巴细胞生成素。小结:尽管抗体已经人源化,但苯拉利单抗、杜匹单抗、美博利珠单抗、奥马珠单抗、雷司利珠单抗和替塞单抗显然都会在一定程度上诱发抗药性抗体。这些抗体可能会导致不良事件,包括输液反应、血清病、过敏性休克以及因治疗功能丧失而导致的潜在疾病活动。监测抗药抗体(ADA)可预测某些患者未来的治疗失败,从而允许停止治疗和转换治疗方案,从而有可能限制疾病的突破。
{"title":"Immunogenicity of biologics used in the treatment of asthma.","authors":"Omario A M Neunie, Wardah Rabbani, David Baker, Emma S Chambers, Paul E Pfeffer, Angray S Kang","doi":"10.3233/HAB-240002","DOIUrl":"10.3233/HAB-240002","url":null,"abstract":"<p><strong>Objective: </strong>Asthma is a major global disease affecting adults and children, which can lead to hospitalization and death due to breathing difficulties. Although targeted monoclonal antibody therapies have revolutionized treatment of severe asthma, some patients still fail to respond. Here we critically evaluate the literature on biologic therapy failure in asthma patients with particular reference to anti-drug antibody production, and subsequent loss of response, as the potential primary cause of drug failure in asthma patients.</p><p><strong>Recent findings: </strong>Encouragingly, asthma in most cases responds to treatment, including the use of an increasing number of biologic drugs in moderate to severe disease. This includes monoclonal antibody inhibitors of immunoglobulin E and cytokines, including interleukin 4, 5, or 13 and thymic stromal lymphopoietin. These limit mast cell and eosinophil activity that cause the symptomatic small airways obstruction and exacerbations.</p><p><strong>Summary: </strong>Despite humanization of the antibodies, it is evident that benralizumab; dupilumab; mepolizumab; omalizumab; reslizumab and tezepelumab all induce anti-drug antibodies to some extent. These can contribute to adverse events including infusion reactions, serum sickness, anaphylaxis and potentially disease activity due to loss of therapeutic function. Monitoring anti-drug antibodies (ADA) may allow prediction of future treatment-failure in some individuals allowing treatment cessation and switching therefore potentially limiting disease breakthrough.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"121-128"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serostatus of Coxsackie B in a sample of women with miscarriage in Baghdad, Iraq. 伊拉克巴格达流产妇女样本中柯萨奇 B 的血清状态。
Q3 Medicine Pub Date : 2024-01-01 DOI: 10.3233/HAB-240005
Mervet B Jasim, Asmaa B Al-Obaidi, Enas Adnan Abdulrasul, Haider Faisal Ghazi

Background: The antibody that crosses transplacentally from mother to fetus is very important origin of protective passive immunity against infection neonatal with enterovirus. Important varieties of coxsackievirus B3 (CVB3) are responsible for infections in newborns. The purpose from this study is to investigate in the prevalence of Coxsackie B virus in a sample of Iraqi women with miscarriage and potential role of miscarriage risk.

Methods: Between November 2022 and June 2023, we included 91 parturient women (gestational age: 4-20 weeks) who were between the ages of 15 and 40. Every participant completed a questionnaire, and blood was drawn to assess maternal antibodies against CVB3.

Results: The blood seropositive rates were 46 out 91(50.54%), 2 out 46 were IgM positive (4.34%), (8-12 weeks) 23 from 46 (50%) (p-value 0.0294) gestational age more frequent among aborted women that positive for anti-coxsackie B antibody, The 25-35 age group was significantly overrepresented (51/91, 56%) compared to other age groups.

Conclusion: This investigation posits Coxsackie B virus (CBV) as a possible etiology for miscarriage in the Iraqi female population. Further studies employing larger cohorts and robust methodologies, beyond the current detection technique, are warranted to corroborate these observations and elucidate the potential mechanisms by which CBV might induce miscarriage.

导言:经胎盘从母体传给胎儿的抗体是新生儿感染肠道病毒后产生保护性被动免疫的重要来源。柯萨奇病毒 B3(CVB3)是导致新生儿感染的重要病毒。本研究的目的是调查柯萨奇 B 病毒在伊拉克流产妇女样本中的流行情况以及对流产风险的潜在作用:方法:在 2022 年 11 月至 2023 年 6 月期间,我们纳入了 91 名年龄在 15 岁至 40 岁之间的流产妇女(孕龄:4-20 周)。每位参与者都填写了一份调查问卷,并抽血评估母体的 CVB3 抗体:结果:血清阳性率为 91 人中的 46 人(50.54%),46 人中有 2 人 IgM 阳性(4.34%),(8-12 周)46 人中有 23 人(50%)(P 值为 0.0294),胎龄越大,抗柯萨奇 B 抗体阳性的流产妇女越多,与其他年龄组相比,25-35 岁年龄组的比例明显偏高(51/91,56%):这项调查认为柯萨奇 B 病毒(CBV)可能是伊拉克女性流产的病因之一。除了目前的检测技术外,还需要采用更大的群体和更可靠的方法进行进一步研究,以证实这些观察结果,并阐明 CBV 可能诱发流产的潜在机制。
{"title":"Serostatus of Coxsackie B in a sample of women with miscarriage in Baghdad, Iraq.","authors":"Mervet B Jasim, Asmaa B Al-Obaidi, Enas Adnan Abdulrasul, Haider Faisal Ghazi","doi":"10.3233/HAB-240005","DOIUrl":"10.3233/HAB-240005","url":null,"abstract":"<p><strong>Background: </strong>The antibody that crosses transplacentally from mother to fetus is very important origin of protective passive immunity against infection neonatal with enterovirus. Important varieties of coxsackievirus B3 (CVB3) are responsible for infections in newborns. The purpose from this study is to investigate in the prevalence of Coxsackie B virus in a sample of Iraqi women with miscarriage and potential role of miscarriage risk.</p><p><strong>Methods: </strong>Between November 2022 and June 2023, we included 91 parturient women (gestational age: 4-20 weeks) who were between the ages of 15 and 40. Every participant completed a questionnaire, and blood was drawn to assess maternal antibodies against CVB3.</p><p><strong>Results: </strong>The blood seropositive rates were 46 out 91(50.54%), 2 out 46 were IgM positive (4.34%), (8-12 weeks) 23 from 46 (50%) (p-value 0.0294) gestational age more frequent among aborted women that positive for anti-coxsackie B antibody, The 25-35 age group was significantly overrepresented (51/91, 56%) compared to other age groups.</p><p><strong>Conclusion: </strong>This investigation posits Coxsackie B virus (CBV) as a possible etiology for miscarriage in the Iraqi female population. Further studies employing larger cohorts and robust methodologies, beyond the current detection technique, are warranted to corroborate these observations and elucidate the potential mechanisms by which CBV might induce miscarriage.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"61-65"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Free radicals and oxidative stress: Mechanisms and therapeutic targets. 自由基和氧化应激:机制与治疗目标:评论文章。
Q3 Medicine Pub Date : 2024-01-01 DOI: 10.3233/HAB-240011
Huda A Hassan, Hind Sh Ahmed, Dheefaf F Hassan

Background: Free radicals are small extremely reactive species that have unpaired electrons. Free radicals include subgroups of reactive species, which are all a product of regular cellular metabolism. Oxidative stress happens when the free radicals production exceeds the capacity of the antioxidant system in the body's cells.

Objective: The current review clarifies the prospective role of antioxidants in the inhibition and healing of diseases.

Methods: Information on oxidative stress, free radicals, reactive oxidant species, and natural and synthetic antioxidants was obtained by searching electronic databases like PubMed, Web of Science, and Science Direct, with articles published between 1987 and 2023 being included in this review.

Results: Free radicals exhibit a dual role in living systems. They are toxic byproducts of aerobic metabolism that lead to oxidative injury and tissue disorders and act as signals to activate appropriate stress responses. Endogenous and exogenous sources of reactive oxygen species are discussed in this review. Oxidative stress is a component of numerous diseases, including diabetes mellitus, atherosclerosis, cardiovascular disease, Alzheimer's disease, Parkinson's disease, and cancer. Although various small molecules assessed as antioxidants have shown therapeutic prospects in preclinical studies, clinical trial outcomes have been inadequate. Understanding the mechanisms through which antioxidants act, where, and when they are active may reveal a rational approach that leads to more tremendous pharmacological success. This review studies the associations between oxidative stress, redox signaling, and disease, the mechanisms through which oxidative stress can donate to pathology, the antioxidant defenses, the limits of their effectiveness, and antioxidant defenses that can be increased through physiological signaling, dietary constituents, and probable pharmaceutical interference. Prospective clinical applications of enzyme mimics and current progress in metal- and non-metal-based materials with enzyme-like activities and protection against chronic diseases have been discussed.

Conclusion: This review discussed oxidative stress as one of the main causes of illnesses, as well as antioxidant systems and their defense mechanisms that can be useful in inhibiting these diseases. Thus, the positive and deleterious effects of antioxidant molecules used to lessen oxidative stress in numerous human diseases are discussed. The optimal level of vitamins and minerals is the amount that achieves the best feed benefit, best growth rate, and health, including immune efficiency, and provides sufficient amounts to the body.

背景:自由基是具有未成对电子的极高活性小分子物质。自由基包括活性物质亚群,它们都是细胞正常新陈代谢的产物。当自由基的产生超过人体细胞抗氧化系统的能力时,就会出现氧化应激:本综述阐明了抗氧化剂在抑制和治疗疾病方面的前瞻性作用:方法:通过搜索PubMed、Web of Science和Science Direct等电子数据库,获取有关氧化应激、自由基、活性氧化物种以及天然和合成抗氧化剂的信息,并将1987年至2023年间发表的文章纳入本综述:自由基在生命系统中具有双重作用。它们是有氧代谢的有毒副产物,会导致氧化损伤和组织失调,同时也是激活适当应激反应的信号。本综述将讨论活性氧的内源性和外源性来源。氧化应激是许多疾病的组成部分,包括糖尿病、动脉粥样硬化、心血管疾病、阿尔茨海默病、帕金森病和癌症。虽然各种被评估为抗氧化剂的小分子在临床前研究中显示出了治疗前景,但临床试验结果却不尽如人意。了解抗氧化剂的作用机制、作用部位和作用时间可能会发现一种合理的方法,从而取得更大的药理成功。这篇综述研究了氧化应激、氧化还原信号转导和疾病之间的关联,氧化应激导致病变的机制,抗氧化剂的防御能力、其有效性的极限,以及通过生理信号转导、饮食成分和可能的药物干扰可以提高的抗氧化剂防御能力。此外,还讨论了酶模拟物的临床应用前景,以及具有类似酶活性的金属和非金属材料在预防慢性疾病方面的最新进展:本综述讨论了作为疾病主要原因之一的氧化应激,以及可用于抑制这些疾病的抗氧化系统及其防御机制。因此,本文讨论了抗氧化剂分子用于减轻氧化应激对多种人类疾病的积极和有害影响。维生素和矿物质的最佳含量是指能达到最佳饲料效益、最佳生长速度和健康(包括免疫效率),并能为机体提供足够量的维生素和矿物质。
{"title":"Free radicals and oxidative stress: Mechanisms and therapeutic targets.","authors":"Huda A Hassan, Hind Sh Ahmed, Dheefaf F Hassan","doi":"10.3233/HAB-240011","DOIUrl":"10.3233/HAB-240011","url":null,"abstract":"<p><strong>Background: </strong>Free radicals are small extremely reactive species that have unpaired electrons. Free radicals include subgroups of reactive species, which are all a product of regular cellular metabolism. Oxidative stress happens when the free radicals production exceeds the capacity of the antioxidant system in the body's cells.</p><p><strong>Objective: </strong>The current review clarifies the prospective role of antioxidants in the inhibition and healing of diseases.</p><p><strong>Methods: </strong>Information on oxidative stress, free radicals, reactive oxidant species, and natural and synthetic antioxidants was obtained by searching electronic databases like PubMed, Web of Science, and Science Direct, with articles published between 1987 and 2023 being included in this review.</p><p><strong>Results: </strong>Free radicals exhibit a dual role in living systems. They are toxic byproducts of aerobic metabolism that lead to oxidative injury and tissue disorders and act as signals to activate appropriate stress responses. Endogenous and exogenous sources of reactive oxygen species are discussed in this review. Oxidative stress is a component of numerous diseases, including diabetes mellitus, atherosclerosis, cardiovascular disease, Alzheimer's disease, Parkinson's disease, and cancer. Although various small molecules assessed as antioxidants have shown therapeutic prospects in preclinical studies, clinical trial outcomes have been inadequate. Understanding the mechanisms through which antioxidants act, where, and when they are active may reveal a rational approach that leads to more tremendous pharmacological success. This review studies the associations between oxidative stress, redox signaling, and disease, the mechanisms through which oxidative stress can donate to pathology, the antioxidant defenses, the limits of their effectiveness, and antioxidant defenses that can be increased through physiological signaling, dietary constituents, and probable pharmaceutical interference. Prospective clinical applications of enzyme mimics and current progress in metal- and non-metal-based materials with enzyme-like activities and protection against chronic diseases have been discussed.</p><p><strong>Conclusion: </strong>This review discussed oxidative stress as one of the main causes of illnesses, as well as antioxidant systems and their defense mechanisms that can be useful in inhibiting these diseases. Thus, the positive and deleterious effects of antioxidant molecules used to lessen oxidative stress in numerous human diseases are discussed. The optimal level of vitamins and minerals is the amount that achieves the best feed benefit, best growth rate, and health, including immune efficiency, and provides sufficient amounts to the body.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"151-167"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increase in the specificity of immunoassay methods by direct targeting different epitopes; sequential chain reactions. 通过直接针对不同的表位提高免疫测定方法的特异性;连续链反应。
Q3 Medicine Pub Date : 2024-01-01 DOI: 10.3233/HAB-240019
Yasin Ahmadi, Hamid Ahmadi, Leili Aghebati-Maleki

Background: Immunoassay methods typically involve the use of antibodies, which are either labeled with an enzyme to generate a detectable product or directly tagged with a radioactive or fluorescent substrate.

Methods: One approach to enhance the specificity of immuno-detection methods is by employing a combination of different antibodies, such as primary and secondary.

Results: However, relying solely on one antibody targeting another may not offer the highest level of precision for improving immunoassay specificity; A novel strategy for enhancing the specificity of immunoassay techniques involves directly targeting different epitopes of an antigen.

Conclusions: This approach entails utilizing sequential chain reactions facilitated by distinct enzymes bound to various antibodies, each directed at specific epitopes on the antigen. Such an innovative method holds promise for advancing the specificity of immunoassay methods.

背景:免疫测定方法通常涉及抗体的使用,抗体或被酶标记以产生可检测的产物,或直接被放射性或荧光底物标记:方法:提高免疫检测方法特异性的一种方法是结合使用不同的抗体,如一抗和二抗:然而,仅仅依靠一种抗体靶向另一种抗体可能无法提供最高水平的精确度来提高免疫测定的特异性;一种提高免疫测定技术特异性的新策略是直接靶向抗原的不同表位:这种方法需要利用与各种抗体结合的不同酶促进连续链反应,每种酶都针对抗原上的特定表位。这种创新方法有望提高免疫测定方法的特异性。
{"title":"Increase in the specificity of immunoassay methods by direct targeting different epitopes; sequential chain reactions.","authors":"Yasin Ahmadi, Hamid Ahmadi, Leili Aghebati-Maleki","doi":"10.3233/HAB-240019","DOIUrl":"10.3233/HAB-240019","url":null,"abstract":"<p><strong>Background: </strong>Immunoassay methods typically involve the use of antibodies, which are either labeled with an enzyme to generate a detectable product or directly tagged with a radioactive or fluorescent substrate.</p><p><strong>Methods: </strong>One approach to enhance the specificity of immuno-detection methods is by employing a combination of different antibodies, such as primary and secondary.</p><p><strong>Results: </strong>However, relying solely on one antibody targeting another may not offer the highest level of precision for improving immunoassay specificity; A novel strategy for enhancing the specificity of immunoassay techniques involves directly targeting different epitopes of an antigen.</p><p><strong>Conclusions: </strong>This approach entails utilizing sequential chain reactions facilitated by distinct enzymes bound to various antibodies, each directed at specific epitopes on the antigen. Such an innovative method holds promise for advancing the specificity of immunoassay methods.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"181-186"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of serum biomarkers level transforming growth factor-β and tumor necrosis factor-α with diabetic neuropathy. 血清生物标志物水平转化生长因子-β和肿瘤坏死因子-α与糖尿病神经病变的关系
Q3 Medicine Pub Date : 2024-01-01 DOI: 10.3233/HAB-240031
Dhifaf Abdulrhaman, Hayfaa Fahad, Nawar Khalil

Background: Many studies have examined the role of inflammation in the development of diabetic neuropathy (DPN).

Objective: Evaluate the relation of the serum level of Transforming Growth Factor-β and Tumor Necrosis Factor-α and development of diabetic peripheral neuropathy DPN.

Methods: In a case-control study, randomly selected 140 diabetic patients were included, the randomly selected patients were divided equally and matched into a case group who have diabetic peripheral neuropathy and diabetic neuropathy-free patients as a control group. For both groups whole blood sample was examined to compare for (TGF-β), and (TNF-α) levels determination by ELISA technique.

Results: The age of the study samples ranged from 25 to 80 years with a male ratio of 1.45:1 although the sex differences between both groups were not significant. The mean levels of (TNF-α) and (TGF-β) was significantly higher among cases group than that of controls group (254.86 ± 75.9 vs158.01 ± 50.600) for TNF-α and for TGF- β (312.85 ± 62.27 vs. 217.82 ± 52.95) respectively. Both TNF-α and TGF-β have high sensitivity and specificity in detection of DPN. The sensitivity of TNF-α was 95.7% and specificity of 61.4% area under the ROC curve (AUC) of 0.870 ± 0.029, while the sensitivity of TGF-β was 91.4%, and specificity of 67.1 with good area under the ROC curve (AUC) of 0.891 ± 0.026 (P=0.000).

Conclusions: TNF-α and TGF -β are significantly elevated levels in patients with DPN, these cytokines could be used as indicators for the development of DPN.

背景:许多研究都探讨了炎症在糖尿病神经病变(DPN)发生过程中的作用:许多研究都探讨了炎症在糖尿病神经病变(DPN)发生中的作用:评估血清中转化生长因子-β和肿瘤坏死因子-α的水平与糖尿病周围神经病变DPN发病的关系:在一项病例对照研究中,随机抽取 140 名糖尿病患者,将其平均分为患有糖尿病周围神经病变的病例组和无糖尿病周围神经病变的对照组。对两组患者的全血样本进行检测,通过 ELISA 技术比较(TGF-β)和(TNF-α)水平:研究样本的年龄从 25 岁到 80 岁不等,男女比例为 1.45:1,但两组样本的性别差异并不明显。病例组(TNF-α)和(TGF-β)的平均水平明显高于对照组(TNF-α为 254.86 ± 75.9 vs 158.01 ± 50.600,TGF- β为 312.85 ± 62.27 vs 217.82 ± 52.95)。TNF-α和TGF-β在检测DPN方面都具有较高的灵敏度和特异性。TNF-α的灵敏度为95.7%,特异性为61.4%,ROC曲线下面积(AUC)为0.870 ± 0.029;TGF-β的灵敏度为91.4%,特异性为67.1,ROC曲线下面积(AUC)为0.891 ± 0.026(P=0.000):结论:TNF-α和TGF-β在DPN患者中明显升高,这些细胞因子可作为DPN发病的指标。
{"title":"Association of serum biomarkers level transforming growth factor-β and tumor necrosis factor-α with diabetic neuropathy.","authors":"Dhifaf Abdulrhaman, Hayfaa Fahad, Nawar Khalil","doi":"10.3233/HAB-240031","DOIUrl":"10.3233/HAB-240031","url":null,"abstract":"<p><strong>Background: </strong>Many studies have examined the role of inflammation in the development of diabetic neuropathy (DPN).</p><p><strong>Objective: </strong>Evaluate the relation of the serum level of Transforming Growth Factor-β and Tumor Necrosis Factor-α and development of diabetic peripheral neuropathy DPN.</p><p><strong>Methods: </strong>In a case-control study, randomly selected 140 diabetic patients were included, the randomly selected patients were divided equally and matched into a case group who have diabetic peripheral neuropathy and diabetic neuropathy-free patients as a control group. For both groups whole blood sample was examined to compare for (TGF-β), and (TNF-α) levels determination by ELISA technique.</p><p><strong>Results: </strong>The age of the study samples ranged from 25 to 80 years with a male ratio of 1.45:1 although the sex differences between both groups were not significant. The mean levels of (TNF-α) and (TGF-β) was significantly higher among cases group than that of controls group (254.86 ± 75.9 vs158.01 ± 50.600) for TNF-α and for TGF- β (312.85 ± 62.27 vs. 217.82 ± 52.95) respectively. Both TNF-α and TGF-β have high sensitivity and specificity in detection of DPN. The sensitivity of TNF-α was 95.7% and specificity of 61.4% area under the ROC curve (AUC) of 0.870 ± 0.029, while the sensitivity of TGF-β was 91.4%, and specificity of 67.1 with good area under the ROC curve (AUC) of 0.891 ± 0.026 (P=0.000).</p><p><strong>Conclusions: </strong>TNF-α and TGF -β are significantly elevated levels in patients with DPN, these cytokines could be used as indicators for the development of DPN.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"193-199"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Antibodies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1